Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 6/20 | 0.58 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.58 |
| ▸ | NEK1 | Q96PY6 | 6/20 | 0.51 |
| ▸ | IKBKB | O14920 | 7/20 | 0.46 |
| ▸ | CHUK | O15111 | 6/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101575 | 1.00 | ATR (0.58) | ATRCHEK1PIK3CANEK1IKBKB | |
| SCHEMBL16692485 | 0.84 | PRKCI (0.48) | ATRCHEK1PIK3CAIKBKBCHUK | |
| SCHEMBL98273 | 0.81 | AURKB (0.56) | IKBKBCHUKPRKCIROCK1 | |
| SCHEMBL29540441 | 0.81 | AURKB (0.56) | IKBKBCHUKPRKCIROCK1 | |
| SCHEMBL29540628 | 0.79 | PRKCI (0.44) | IKBKBCHUKPRKCIROCK1 | |
| SCHEMBL99826 | 0.79 | PRKCI (0.44) | IKBKBCHUKPRKCIROCK1 | |
| SCHEMBL29540640 | 0.78 | CIT (0.48) | ROCK1 | |
| SCHEMBL98969 | 0.78 | CIT (0.48) | ROCK1 | |
| SCHEMBL99682 | 0.77 | PRKCI (0.49) | IKBKBCHUKPIK3C3PRKCIROCK1 | |
| SCHEMBL29541194 | 0.77 | PRKCI (0.49) | IKBKBCHUKPIK3C3PRKCIROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | ATR 610/4885CHEK1 493/4885PIK3CA 72/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | ATR 610/4885CHEK1 493/4885PIK3CA 72/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | ATR 610/4885CHEK1 493/4885PIK3CA 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.